Faster weight gain during HIV treatment can increase the risk of comorbidities.

In response to the problem of excessive weight gain during HIV treatment and the potential to increase the risk of comorbidities, Professor Princy Kumar presented DRIVE-SHIFT, a clinical trial of the new non-nucleoside reverse transcriptase inhibitor DELSTRIGO (Dolaverin/ramiftin/Tinofovir)He noted that the results of the DRIVE-SHIFT study showed that HIV-infected people using DELSTRIGO had the same annual weight gain levels as the general populationThe new HIV treatment program is expected to accelerate its entry into ChinaDELSTRIGO was approved by the U.SFDA in August 2018 as a daily oral fixed-dose compound tablet consisting of Dolaverin, ramivudine, and tinofovir, for hiv-1 infections who have been or are not resistant to non-nucleoside inhibitors (NNRTI) antiviral drugsAlso approved by the FDA is Dolaverin's single-drug formulation PIFELTRODolaverin's earlier launch of the third phase of the trial, drive-FORWARD data, also showed friendly results for blood lipid levelsFrom the study baseline to follow-up 96 weeks, the randomly assigned trial group taking PIFELTRO (Dolaverin 100 mg) performed better on the baseline effect analysis of LDL-C and non-HDL-C (non-HDL-C) compared to the control group that took Darnarave-Litonove (DRV/r)Similar benefits were also demonstrated in the DRIVE-AHEAD trialThe results of the randomly assigned participant DELSTRIGO (Dolaverin/Ramiftin/Tinofowe) group compared the efivellelen/Enquatabin/Tenofowe group showed that the experimental group using DELSTRIGO showed better blood lipid levels at 48 weeksCurrently, PIFELTRO (Dolaverin tablets) and DELSTRIGO (Dolaverin/Ramifdine/Tenofove tablets) have been included in the Priority Review of the State Drug Administration in China, and these two drugs are expected to accelerate their entry into China by 2020 with priority reviewSeveral heavy-weight studies have shown the promise of new drugs This AIDS conference also revealed another new type of nucleoside reverse transcriptase transpostorase inhibitor , Islatravir (ISL)Studies have shown that ISL is more than ten times more effective than other approved antiretroviral drugs, is active against HIV with drug-resistant mutations, and has a long half-life in the bodyAt the same time, the researchers made an assessment of the safety and effectiveness of ISL-DOR (Dolaverin), and at present, good tolerance has been shown in various doses in clinical trialsISL has the potential for different dosage forms in the future, and studies on PrEP and HIV treatment are under way